About the Company
syndax pharmaceuticals is a biotechnology company located at 35 gatehouse dr., building d, floor 3, waltham, ma 02451.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SNDX News
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
WALTHAM, Mass., March 18, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced ...
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call Transcript
February 27, 2024 Syndax Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1 EPS, expectations were ...
SNDX Apr 2024 17.500 put
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call Transcript February 27, 2024 Syndax Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1 EPS, expectations were $ ...
Buy Rating for Syndax Pharmaceuticals Amidst Strategic Progress and Regulatory Milestones
In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Buy rating on Syndax Pharmaceuticals (SNDX – Research ...
Syndax Pharmaceuticals Inc SNDX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Syndax Pharmaceuticals Stock (NASDAQ:SNDX), Quotes and News Summary
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) shares are trading higher after the company shared data from multiple trials of revumenib in combination with standard-of-care agents in patients with ...
Syndax: Q4 Earnings Snapshot
WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Syndax Pharmaceuticals Inc. (SNDX) on Tuesday reported a loss of $72.5 million in its fourth quarter. The Waltham, Massachusetts-based company said ...
Q4 2023 Syndax Pharmaceuticals Inc Earnings Call
Sharon Klahre; Head of IR; Syndax Pharmaceuticals, Inc. Michael Metzger; CEO & Director; Syndax Pharmaceuticals, Inc. Neil Gallagher; President & Head of Research and ...
Syndax Pharmaceuticals: Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
Steven Closter brings more than 30 years of commercial experience in the biopharmaceutical industry to Syndax - - Company on track for two potential first- and best-in-class product launches in 2024 ...
Syndax Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...